Bijoya Bhattacharjee*¹, Asmita Roy² and Joyeta Ghosh²

¹Department of Dietetics and Applied Nutrition, Amity University Kolkata, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore
²Department of Dietetics and Applied Nutrition, Amity University Kolkata

*Corresponding Author: Department of Dietetics and Applied Nutrition, Amity University Kolkata, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore

Received: March 13, 2023; Published: March 20, 2023

Abstract

A gastrointestinal disorder recognized by altered bowel routines in relation to cramping, bloating, abdominal pain, gas, chronic diarrhea, and constipation that affects the large intestine is diagnosed as Irritable Bowel Syndrome (IBS). On the other hand, the accumulation of fat and triglycerides in the liver leading to steatosis in patients who consume little or no alcohol relates to metabolic syndrome, obesity, diabetes, and insulin resistance recognized as Non-Alcoholic Fatty Liver Disease (NAFLD). Around 73 literature reviews were evaluated to examine the relationship between impaired intestinal motility and deposition of excess visceral adipose tissue in the organs affecting the metabolic mechanisms, IBS and NAFLD. This study is conducted to find the interrelationship between IBS and NAFLD through various predominant pathophysiological factors that are all interconnected which include Obesity, Gut Microbiota, Bile Acid Diarrhea, Small Intestinal Bacterial Overgrowth (SIBO), and Gut-Microbiome-Liver Axis. After studying various published literature, it was established that IBS and NAFLD are interlinked in nature and is associated with Gut microbiota, obesity, bile acid malabsorption and SIBO disrupting the gut-liver axis. IBS influences inflammation and immune activation through excess adiposity creating a disbalance in the composition of good microbes in the gut increasing intestinal permeability, hence, metabolites produced by microbes, such as lactate and ethanol, have the ability to directly trigger inflammatory cascades in the liver, creates an interlinked loop between IBS and NAFLD.

Keywords: IBS; BA-diarrhea; NAFLD; Gut Microbiota; Obesity; SIBO

References

1. Drossman Douglas A. “The functional gastrointestinal disorders and the Rome III process”. Gastroenterology 5 (2006): 1377-1390.
2. Horwitz B J and R S Fisher. “The irritable bowel syndrome”. The New England Journal of Medicine24 (2001): 1846-1850.
3. Drossman Douglas A., et al. “AGA technical review on irritable bowel syndrome”. Gastroenterology 6 (2002): 2108-2131.
4. Talley Nicholas J and Robin Spiller. “Irritable bowel syndrome: a little understood organic bowel disease?”. Lancet (London, England)9332 (2002): 555-564.
5. McCullough Arthur J. “Pathophysiology of nonalcoholic steatohepatitis”. Journal of Clinical Gastroenterology1 (2006): S17-29.
6. Kanwar Pushpjeet and Kris V Kowdley. “The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis”. Clinics in Liver Disease2 (2016): 225-243.
7. Angulo Paul. “Nonalcoholic fatty liver disease”. The New England Journal of Medicine16 (2002): 1221-1231.
8. Khan Nazish Iqbal., et al. “Obesity: an independent risk factor for systemic oxidative stress”. Pakistan Journal of Pharmaceutical Sciences1 (2006): 62-65.
9. Kim Francis., et al. “Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta”. Arteriosclerosis, Thrombosis and Vascular Biology5 (2005): 989-994.
10. DiSabato Damon J., et al. “Neuroinflammation: the devil is in the details”. Journal of Neurochemistry 139 (2016): 136-153.
11. Abella Vanessa., et al. “The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases”. Biomarkers : Biochemical Indicators of Exposure, Response and Susceptibility to Chemicals8 (2015): 565-571.
12. Moschen Alexander R., et al. “Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations”. Cell Host and Microbe4 (2016): 455-469.
13. Vijay-Kumar Matam., et al. “Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5”. Science (New York, N.Y.) 328,5975 (2010): 228-231.
14. van Greevenbroek M M J., et al. “Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences”. The Netherlands Journal of Medicine4 (2013): 174-187.
15. Paterson B M., et al. “The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study”. Alimentary Pharmacology and Therapeutics5 (2007): 757-766.
16. Ohman Lena and Magnus Simrén. “Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions”. Nature Reviews. Gastroenterology and Hepatology3 (2010): 163-173.
17. Reddymasu Savio C., et al. “Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?”. BMC Gastroenterology23.
18. Gabrielli M., et al. “Diagnosis of small intestinal bacterial overgrowth in the clinical practice”. European Review for Medical and Pharmacological Sciences2 (2013): 30-35.
19. Emerenziani Sara., et al. “Role of Overweight and Obesity in Gastrointestinal Disease”. Nutrients 12,1,111 (2019).
20. Sadik Riadh., et al. “The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome”. European Journal of Gastroenterology and Hepatology1 (2010): 102-108.
21. Franco Lissa., et al. “Irritable Bowel Syndrome Symptoms in Nonalcoholic Fatty Liver Disease Patients Are an Indicator of Depression and Anxiety”. Journal of Clinical Gastroenterology (2022).
22. Marchesini Giulio., et al. “Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome”. Hepatology (Baltimore, Md.) 37,4 (2003): 917-923.
23. Thursby Elizabeth and Nathalie Juge. “Introduction to the human gut microbiota”. The Biochemical Journal11 (2017): 1823-1836.
24. Kastl Arthur J Jr., et al. “The Structure and Function of the Human Small Intestinal Microbiota: Current Understanding and Future Directions”. Cellular and Molecular Gastroenterology and Hepatology1 (2020): 33-45.
25. Scalera Antonella., et al. “What does irritable bowel syndrome share with non-alcoholic fatty liver disease?”. World Journal of Gastroenterology33 (2013): 5402-5420.
26. Frost Fabian., et al. “Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function”. Gut 70,3 (2021): 522-530.
27. Racanelli Vito and Barbara Rehermann. “The liver as an immunological organ”. Hepatology (Baltimore, Md.)2 (2006): S54-62.
28. Akira S., et al. “Toll-like receptors: critical proteins linking innate and acquired immunity”. Nature Immunology 8 (2001): 675-680.
29. Buckley Aaron and Jerrold R Turner. “Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease”. Cold Spring Harbor Perspectives in Biology1 (2018): a029314.
30. Miele Luca., et al. “Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease”. Hepatology (Baltimore, Md.)6 (2009): 1877-1887.
31. Giorgio Valentina., et al. “Intestinal permeability is increased in children with non-alcoholic fatty liver disease and correlates with liver disease severity”. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 46,6 (2014): 556-560.
32. Zhang Zhengxiao., et al. “Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review”. Nutrients 11,10 (2019): 2291.
33. Bhattarai Yogesh., et al. “Irritable bowel syndrome: a gut microbiota-related disorder?”. American Journal of Physiology. Gastrointestinal and Liver Physiology 312,1 (2017): G52-G62.
34. Cani, Patrice D., et al. “Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity”. Gut Microbes4 (2012): 279-288.
35. Appleby Richard N., et al. “Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study”. PloS One1 (2019): e0211348.
36. Pattni S S., et al. “Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention”. Alimentary Pharmacology and Therapeutics 38,8 (2013): 967-976.
37. Bajor Antal., et al. “Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS”. Gut1 (2015): 84-92.
38. Pattni Sanjeev S., et al. “Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea”. Clinical and Translational Gastroenterology7 (2012): e18.
39. Chiang John Y L. “Bile acid metabolism and signaling”. Comprehensive Physiology3 (2013): 1191-1212.
40. Di Ciaula Agostino., et al. “Bile Acid Physiology”. Annals of Hepatology 16 (2017): s4-s14.
41. Nie Yang-fan., et al. “Cross-talk between bile acids and intestinal microbiota in host metabolism and health”. Journal of Zhejiang University. Science. B6 (2015): 436-446.
42. Kiriyama Yoshimitsu and Hiromi Nochi. “Physiological Role of Bile Acids Modified by the Gut Microbiome”. Microorganisms1 (2021): 68.
43. Ferrell Jessica M and John Y L Chiang. “Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets”. Diabetes and Metabolism Journal 43,3 (2019): 257-272.
44. Rizzo Giovanni., et al. “Role of FXR in regulating bile acid homeostasis and relevance for human diseases”. Current Drug Targets. Immune, Endocrine and Metabolic Disorders3 (2005): 289-303.
45. Chiang John Y L and Jessica M Ferrell. “Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis”. Liver Research2 (2020): 47-63.
46. Jiao Yang., et al. “Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis”. Acta Pharmacologica Sinica1 (2015): 44-50.
47. Aron-Wisnewsky Judith., et al. “Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders”. Nature Reviews. Gastroenterology and Hepatology5 (2020): 279-297.
48. Ford Alexander C., et al. “Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis”. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 7,12 (2009): 1279-1286.
49. Ghoshal Uday C., et al. “A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome”. Journal of Gastroenterology and Hepatology6 (2020): 922-931.
50. Masarone Mario., et al. “Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease”. Oxidative Medicine and Cellular Longevity (2018) 9547613.
51. Zhu Lixin., et al. “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH”. Hepatology (Baltimore, Md.) 2 (2013): 601-609.
52. de Faria Ghetti Fabiana., et al. “Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis”. European Journal of Nutrition3 (2018): 861-876.
53. Marra Fabio and Gianluca Svegliati-Baroni. “Lipotoxicity and the gut-liver axis in NASH pathogenesis”. Journal of Hepatology2 (2018): 280-295.
54. Zhu Lixin., et al. “Gut microbiome and nonalcoholic fatty liver diseases”. Pediatric Research1-2 (2015): 245-251.
55. Rivière Audrey., et al. “Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut”. Frontiers in Microbiology 7 (2016): 979.
56. Dumus mark Emmanuel., et al. “Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice". Proceedings of the National Academy of Sciences of the United States of America 33 (2006): 12511-12516.
57. Jin Xi., et al. “Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats”. World Journal of Gastroenterology 13,11 (2007): 1732-1736.
58. Paolella Giulia., et al. “Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease”. World Journal of Gastroenterology42 (2014): 15518-15531.
59. Dai Xin., et al. “Microbial Metabolites: Critical Regulators in NAFLD”. Frontiers in Microbiology 11 (2020): 567-654.
60. Elshaghabee Fouad M F., et al. “Ethanol Production by Selected Intestinal Microorganisms and Lactic Acid Bacteria Growing under Different Nutritional Conditions”. Frontiers in Microbiology 7 (2016): 47.
61. Baker Susan S., et al. “Role of alcohol metabolism in non-alcoholic steatohepatitis”. PloS One3 (2010): e9570.
62. Park Eunju., et al. “Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease”. Cells 10,10 (2021): 2634.
63. Sanders Lisa M and Steven H Zeisel. “Choline: Dietary Requirements and Role in Brain Development”. Nutrition Today4 (2007): 181-186.
64. Cole Laura K., et al. “Phosphatidylcholine biosynthesis and lipoprotein metabolism”. Biochimica et Biophysica Acta5 (2012): 754-761.
65. Jelske N van der Veen., et al. "Phosphatidylcholine Biosynthesis and Lipoprotein Metabolism". Biochimica et Biophysica Acta 1821 (2012): 754-761.
66. Vance Dennis E. “Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis”. Current Opinion in Lipidology 3 (2008): 229-234.
67. Van Herck Mikhaïl A., et al. “Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide”. Nutrients 10 (2017): 1072.
68. Yarong Liu., et al. "Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis”. Mediators of Inflammation 2020 (2020): 4634172.
69. Parséus Ava., et al. “Microbiota-induced obesity requires farnesoid X receptor”. Gut 3 (2017): 429-437.
70. Krueger Emily S., et al. “The Accumulation and Molecular Effects of Trimethylamine N-Oxide on Metabolic Tissues: It's Not All Bad”. Nutrients 8 (202): 2873.
71. Spencer Melanie D., et al. “Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency”. Gastroenterology 140,3 (2011): 976-986.
72. Jha Pooja., et al. “Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH)”. Biochimica et Biophysica Acta 7 (2014): 959-970.
73. , et al. “Prevalence of Constipation and its Relationship with Dietary Habits Among College Going Girls in the Age Group of 18-25 Years of Kolkata, West Bengal, India”. Acta Scientific Gastrointestinal Disorders 6.3 (2023): 03-13.

Citation

Citation: Bijoya Bhattacharjee., et al. “Study of Interrelationship Between Irritable Bowel Syndrome and Non-Alcoholic Fatty Liver Disease". Acta Scientific Gastrointestinal Disorders 6.4 (2023): 08-17.

Copyright

Copyright: © 2023 Bijoya Bhattacharjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.